Pain management最新文献

The nocebo effect, a phenomenon wherein negative expectations can worsen symptoms, is increasingly acknowledged within the context of musculoskeletal conditions. While experimental evidence has, to some extent, examined negative expectations in shoulder pain, their specific relationship with nocebo effects and their manifestation in clinical practice remains unexplored. In this perspective, clinicians and researchers are guided by first examining the psychobiology and neurophysiology underlying nocebo effects from a basic science standpoint, thereby equipping clinicians with a robust understanding of the phenomenon. What are considered the primary potential sources of nocebo effects in individuals with shoulder pain are then outlined - namely, diagnostic labels, diagnostic imaging and special tests, the medicalization of normality, and overtreatment. Practical clinical strategies are subsequently proposed to mitigate nocebo effects arising from these sources. Finally, the research implications for advancing the study of nocebo effects in people with shoulder pain are discussed. Overall, this perspective provides a comprehensive overview of the impact of negative expectations and associated nocebo effects on shoulder pain outcomes. By identifying potential sources of nocebo effects that may emerge in everyday clinical practice, guidance on mitigating related negative expectations in patients with shoulder pain is offered.

Aims: Prescribing restrictions have significantly impacted patients with chronic pain, leading to opioid medication tapering and reduced access. This study examines the consequences of these restrictions and their impact on patient health and pain management strategies.

Patients & methods/materials & methods: This research explores barriers to pain care, especially opioid therapy, adverse health outcomes resulting from reduced access to pain medications, and alternative pain management strategies. The study analyzes data from a cross-sectional survey conducted by the American Chronic Pain Association (ACPA) between November 2014 and January 2015. The survey gathered quantitative data on demographics, healthcare access, pain management strategies, and challenges in obtaining prescribed medications, alongside qualitative responses. Descriptive statistics summarized quantitative findings; chi-square and t-tests compared those with and without medication access difficulties. Thematic analysis revealed recurring themes in qualitative responses.

Results: The study reveals that over half of the respondents faced difficulties obtaining prescribed pain medications, leading to significant adverse health consequences, including unmanaged pain, psychological distress, and suicidal ideation.

Conclusion: These findings highlight the urgent need to address systemic and personal barriers to pain medication access, and the need for patient-centered care that incorporates evidence-based, holistic pain management strategies and shared decision-making between clinicians and patients.

Aims: We do not know if patients find the coordinated treatment of comorbid obesity and low back pain acceptable in clinical practice. The primary purpose of this study is to evaluate patient-level interest in a combined back pain and obesity specialty treatment clinic.

Methods: A survey was sent to patients over 18 with a diagnosis of back pain and a BMI over 30 through their electronic medical records. Statistical analysis was carried out to examine the role of weight and pain stigma in mediating beliefs about weight and back pain on interest in a combined clinic.

Results: 1290 people responded. Respondents reported moderate levels of experienced stigma relating to pain (9.4 ± 6.6) using the 32-point Stigma Scale for Chronic Illness and obesity (3.5 ± 1.1) using the 6-point Weight Bias Internalization Scale. Respondents expressed a moderate belief that back pain and weight were related (70.8% ± 21.7). Most patients (69.2%) were interested in a joint clinic.

Conclusions: In a target population of patients with obesity and back pain, a combined clinic treatment plan is desirable. These results support the need to explore the feasibility and sustainability of innovative, combined, holistic care clinics to treat people with obesity and back pain.

Peripheral nerve field stimulation (PNFS) can effectively manage pain localized to one or two dermatomes that are refractory to conventional approaches, such as chronic low back pain. However, its utility in pain management in the upper limbs is limited due to the risk of lead displacement related to articular and mobile segment constraints.In this technical note, we describe a 58-year-old man with neuropathic pain refractory to extensive medical treatment, and dorsal root entry zone lesion. Considering the patient's favorable response to transcutaneous electrical nerve stimulation, we used a two-step lead placement approach to improve the permanent placement of the electrode leads in the upper limb. After 1 year follow-up, the patient achieved at least 50% pain relief, with no signs of lead displacement or resistance during flexion and extension movements of the involved upper limb, illustrating the success of PNFS.

Background: OnabotulinumtoxinA demonstrates effectiveness in chronic migraine prevention but is hindered by variable patient responses. This study aims to identify modifiable and non-modifiable risk factors influencing the response to onabotulinumtoxinA.

Methods: We conducted a retrospective cohort study at a tertiary hospital involving chronic migraine patients treated with onabotulinumtoxinA. Data on risk factors and patient perceptions were collected through medical records and questionnaires.

Results: A total of 131 patients were included. At 12 months, a significant reduction in headache frequency was observed: from 26 episodes pre-treatment to 13 at 3 months, 12 at 6 months, 11 at 9 months, and 10 at 12 months. A third of patients stopped overusing medication after treatment. Univariate logistic regressions revealed that fibromyalgia was associated with a reduced likelihood of achieving ≥50% response to onabotulinumtoxinA (OR (odds ratio) = 0.213, p = 0.031), while secondary education was associated with an increased likelihood of response (OR = 4.400, p = 0.029). Adjusted logistic regression confirmed that fibromyalgia significantly reduced the likelihood of ≥50% response (aOR (adjusted odds ratio) = 0.064, p = 0.033).

Conclusions: This study confirms the real-world effectiveness of onabotulinumtoxinA in reducing headache frequency. Furthermore, patients with fibromyalgia may have a diminished likelihood of responding positively, underscoring the importance of personalized treatment strategies.

The opioid epidemic continues to pose a significant threat to public health. Naloxone, a potent opioid antagonist, has proven to be a crucial tool in reversing opioid overdoses. Efforts to increase access to overdose reversal agents, initially given by injection in hospitals and emergency environments, resulted in the development of intranasal (IN) forms of naloxone, and more recently, nalmefene. This rapid review examines the currently available IN overdose reversal agents in the United States, focusing on their dosing, efficacy, and prescription status.We conducted a comprehensive search of the FDA Electronic Drug and Listing System (eDRLS) to identify all approved naloxone and nalmefene formulations in 2024. The search yielded nine available overdose reversal agents, including generic formulations of naloxone available over the counter and accessible to the public. Additionally, newer agents, such as nalmefene, offer longer-acting effects and may provide additional benefits in certain overdose scenarios.As the opioid crisis evolves, it is essential to stay informed about the latest advancements in formulations of reversal agents. By understanding the characteristics and availability status of available agents, health care providers, public health officials, and individuals can make informed decisions about the most appropriate overdose treatment strategies.

Diabetic peripheral polyneuropathy (DPN) is the most common cause for diabetic foot complications, including diabetic ulcers, Charcot arthropathy, and lower limb amputations. Spinal Cord Stimulation (SCS) is a safe and effective treatment used for pain reduction in neuropathic/nociceptive pain conditions; the most common stimulation modalities used for the management of painful diabetic neuropathy were conventional paresthesia-based and high-frequency SCS, which stimulate the A beta fibers in the dorsal column of the spinal cord. Differential Target Multiplexed (DTM) SCS is a novel paresthesia-free stimulation technique targeting the supportive glial cells in the nervous system, modulating glial cells and neurons with a rebalance of their interactions. We report a case of severe painful DPN who had immediate pain relief after DTM-SCS implantation, with constant pain relief during the 12 months follow-up. We also investigated the effect of neurostimulation on diabetes control, evaluating the preoperative and postoperative glucose metrics using Continuous Glucose Monitoring (CGM) and compared neurophysiological examination results of the peripheral lower limbs' nerves.

Aim: To characterize real-world healthcare resource utilization (HCRU) and costs in adults with chronic pain of peripheral nerve origin treated with peripheral nerve stimulation (PNS) using the micro-implantable pulse generator (IPG).

Materials & methods: This retrospective observational study (9/1/19-1/31/23) linked patients from the Nalu medical database to the OM1 Real-World Data Cloud (RWDC). Eligible patients received the micro-IPG implant for PNS, were identifiable in both databases, and had ≥ 12 months of RWDC pre/post-implantation claims data. Primary outcomes were all-cause HRCU and medical costs (12 months pre- and post-implantation); secondary outcomes were all-cause pharmacy costs, including opioids, over the same time.

Results: Patients (N = 122) had a higher mean (standard deviation; SD) number of outpatient visits pre-implantation (5.7 [5.4]) than post-implantation (4.9 [5.7]). Mean (SD) total medical costs were 50% lower, from $27,493 ($44,756) to $13,717 ($23,278). Median (first-third quartile [Q1-Q3]) medical costs were 57% lower, from $11,809 ($4,075-$31,788) to $5,094 ($1,815-$13,820). Mean (SD) pharmacy costs (n = 77) were higher post-implantation ($22,470 [$77,203]) than pre-implantation ($20,092 [$64,132]), while median (Q1-Q3) costs were lower (from $2,708 [$222 -11,882] to $2,122 [$50-9,370]). Post-implantation, the proportion of patients using opioids was 31.4% lower.

Conclusion: Patients with PNS using the micro-IPG had reduced HCRU, costs, and opioid use.